

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus ID3804

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • AstraZeneca (anifrolumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Arthritis and Musculoskeletal Alliance • Arthritis Action • Black Health Agency for Equality • Changing Faces • Genetic Alliance UK • Kidney Care UK • Let's Face It • Lupus Trust • Lupus UK • National Kidney Federation • National Rheumatoid Arthritis Society • Pain Concern • Pain UK • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • Scleroderma and Raynaud's UK • South Asian Health Foundation • Specialised Healthcare Alliance • Versus Arthritis <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Genetic Nurses & Counsellors • Association of Renal Industries • Association of Renal Technologists • British Association of Dermatologists • British Dermatological Nursing Group • British Institute of Musculoskeletal Medicine • British Geriatrics Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Cell and Gene Therapy Catapult • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Celltrion (rituximab) • GlaxoSmithKline (belimumab) • Napp Pharmaceuticals (rituximab) • Pfizer (rituximab) • Roche Pharmaceuticals (rituximab) • Sandoz GmbH (rituximab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society • British Epidermo-Epidemiology Society • British Society for Immunology • Centre of Evidence-Based Dermatology, University of Nottingham

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Orthopaedic Association • British Pain Society • British Renal Society • British Skin Foundation • British Society for Allergy and Clinical Immunology • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Human Genetics • British Society for Rheumatology • British Society of Rehabilitation Medicine • British Thoracic Society • Physiotherapy Pain Association • Primary Care Dermatology Society • Primary Care Rheumatology Society • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association • UK Primary Immunodeficiency Network • UK Renal Pharmacy Group • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Northern, Eastern and Western Devon CCG • NHS Kernow CCG • Welsh Government 	<ul style="list-style-type: none"> • Chronic Pain Policy Coalition • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Musculoskeletal Group • Cochrane Peripheral Vascular Disease Group • Cochrane Skin Group • Genomics England • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Pain Relief Foundation • Skin Treatment and Research Trust • Thrombosis Research Institute <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.